Clinical Trials
29 trialsNCT05226598 2026-02-05
MK-7684A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03177291 2025-12-05
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03396445 2025-11-05
MK-5890-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02250326 2024-09-19
abound2L+
Celgene
Phase 2 Completed
NCT02716038 2023-12-12
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Columbia University
Phase 2 Completed
NCT03345810 2023-06-15
DURATION
AIO-Studien-gGmbH
Phase 2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT02862457 2022-08-19
MK-3475-434
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00347412 2022-07-25
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Cellectar Biosciences, Inc.
Phase 3 Completed
NCT00533949 2022-06-21
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00979212 2022-06-15
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT02799862 2021-10-06
NEPTUN
iOMEDICO AG
Completed
NCT01620190 2021-07-16
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
University of Washington
Phase 2 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02392507 2020-11-19
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Phase 2 Completed
NCT02730247 2020-11-19
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
University of Pittsburgh
Phase 2 Completed
NCT01702844 2020-10-08
Single Arm on the Tolerability of Weekly Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02027428 2020-08-17
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Celgene
Phase 3 Completed
NCT00274443 2019-11-12
An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin
Celgene
Phase 2 Completed
NCT01478685 2019-11-12
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
Phase 1 Completed
NCT00540514 2019-10-29
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
Celgene
Phase 3 Completed
NCT02309177 2019-05-31
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Celgene
Phase 1 Completed
NCT02289456 2018-12-07
AboundPS2
Celgene
Phase 2 Completed
NCT02151149 2018-09-24
ABOUND 70+
Celgene
Phase 4 Completed
NCT02172846 2017-12-08
Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 1 Completed
NCT00073723 2016-12-15
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Celgene Corporation
Phase 1/2 Completed
NCT00313599 2014-07-02
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
University of California, San Francisco
Phase 1 Completed